NCT06278337: X-MAIDReg

X-linked Moesin Associated Immunodeficiency

Recruiting now Last updated 25 April 2025

What this trial tests

trial testing genetic restrospective study in Immune Deficiency in 16 participants. Currently enrolling.

Timeline

12 August 2021

Primary endpoint
12 August 2026

12 January 2027

Quick facts

Lead sponsor	Institut National de la Santé Et de la Recherche Médicale, France
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	16
Start date	12 August 2021
Primary completion	12 August 2026
Estimated completion	12 January 2027
Sites	10 locations across France, Japan, Netherlands, Belgium, Australia, United States

Drugs / interventions tested

• genetic restrospective study

Conditions studied

• Immune Deficiency — all drugs for Immune Deficiency →
• Autoimmune Diseases — all drugs for Autoimmune Diseases →
• Infections — all drugs for Infections →
• Diagnosis — all drugs for Diagnosis →

Sponsor

Institut National de la Santé Et de la Recherche Médicale, France — full company profile →

Who can join

Adults 4 to 80, male only, with Immune Deficiency or Autoimmune Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Moesin deficiency was initially described in 7 male participants aged 4 to 69 years and is characterized by lymphopenia of the 3 lineages and moderate neutropenia. Genetically, 6 out of 7 participants had the same missense mutation in the moesin gene located on the X chromosome. The 7th patient has a mutation leading to the premature introduction of a STOP codon into the protein.Clinically the 7 participants with X-linked moesin-associated immunodeficiency all presented with recurrent bacterial infections of the respiratory, gastrointestinal or urinary tracts, and some had severe varicella.Therapeutically, in the absence of a molecular diagnosis and due to his SCID-like phenotype, one patient was treated with geno-identical hematopoietic stem cell transplantation . The remaining are untreated or treated with immunoglobulin substitution and/or prophylactic antibiotics.

Since this study, the moesin gene has been integrated into DNA chips used for the molecular diagnosis of immune deficiencies in several countries. Physicians in Canada, the United States, Japan, South Africa and Europe have contacted us with a total of 16 known participants to date. Because of their very low severe, uncontrolled CMV infection and the absence of treatment recommendations, two 2 American participants were treated with allogeneic transplantation with severe post-transplant complications (1), and one of the participants died as a result of the transplant. Management of XMAID participants therefore varies widely from country to country, depending on age at diagnosis and clinical picture. It ranges from no treatment treatment (associated with recurrent infections and skin manifestations), IgIv substitution and/or antibiotic prophylaxis antibiotic prophylaxis, with low toxicity and apparent efficacy, and allogeneic transplantation, with all the risks risks involved (graft-related toxicity, graft versus host, disease, rejection, risk of infection). The Investigators therefore feel it is important to review the diagnosis, clinical presentation and management of X-MAID participants. The study the investigator propose will enable to understand the presentation of X-MAID participants, establish guidelines and provide the best treatment for each patient according to his or her clinical picture

Publications & conference data

No peer-reviewed publications indexed yet for this trial.